June 2 (Reuters) - Sanofi:

* PRESS RELEASE: SANOFI TO ACQUIRE BLUEPRINT MEDICINES,

EXPANDING

PORTFOLIO IN RARE IMMUNOLOGICAL DISEASE AND ADDING EARLY-STAGE

PIPELINE IN IMMUNOLOGY

* SANOFI TO FINANCE DEAL WITH CASH AND NEW DEBT

* SANOFI EXPECTS TO COMPLETE ACQUISITION IN Q3 2025

* WILL PAY $129.00 PER SHARE IN CASH AT CLOSING,

REPRESENTING AN

EQUITY VALUE OF APPROXIMATELY $9.1 BILLION FOR BLUEPRINT

* ACQUISITION IMMEDIATELY ACCRETIVE TO GROSS MARGIN

* BLUEPRINT SHAREHOLDERS WILL RECEIVE ONE NON-TRADEABLE

CONTINGENT

VALUE RIGHT (CVR) WHICH WILL ENTITLE HOLDER TO RECEIVE TWO

POTENTIAL MILESTONE PAYMENTS OF $2 AND $4 PER CVR FOR

ACHIEVEMENT, RESPECTIVELY, OF FUTURE DEVELOPMENT AND REGULATORY

MILESTONES FOR BLU-808

* TOTAL EQUITY VALUE OF BLUEPRINT TRANSACTION, INCLUDING

POTENTIAL

CVR PAYMENTS, REPRESENTS APPROXIMATELY $9.5 BILLION ON A FULLY

DILUTED BASIS

Source text:

Further company coverage:

(Gdansk Newsroom)